2022 Clinic Nuclear Medicine PET Scan 
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
AuntMinnie
JANUARY 23, 2024
An international survey of treatment centers has revealed significant differences in several aspects of Lu-177 PSMA-617 prostate cancer therapy, including patient imaging protocols, according to a study published January 18 in the Journal of Nuclear Medicine. In addition, different PET radiotracers are used.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
Imaging Technology
MAY 31, 2023
Flavio Forrer , MD, PhD, Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Gallen in Switzerland [vii]. iv] Omni Legend 32 cm has up to 2.2
AuntMinnie
APRIL 15, 2024
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine. “In
Expert insights. Personalized for you.
122 
Let's personalize your content